Pentosan Polysulfate Treatment for Viral ARDS Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no established effective treatment for Acute Respiratory Distress Syndrome (ARDS) caused by SARS-CoV-2, and existing pharmaceutical agents like steroids and antivirals have limitations and side effects, while ventilation systems are insufficient during surges of critically ill patients.
Innovation Solution
Pentosan polysulfate (PPS) is used as a monotherapy or adjunctive treatment for ARDS, targeting multiple aspects of ARDS pathogenesis, including fibrin deposition, complement-mediated lung injury, cytokine response, inflammation, and neutrophil infiltration, with potential to prevent lung fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If steroids are used to treat ARDS, then inflammation is reduced, but immune response is decreased and viral shedding increases
Solution Approach 1:
Pentosan polysulfate acts as an intermediary substance that binds to and neutralizes inflammatory mediators such as cytokines and chemokines, reducing inflammation without suppressing the overall immune response. This mediator approach allows inflammation control while preserving immune function against the virus.
Solution Approach 2:
The treatment changes the chemical parameters of the inflammatory environment by introducing polysulfated polysaccharides that modify the interaction between inflammatory cells and mediators, thereby reducing inflammation through parameter modification rather than broad immune suppression.
2Object-affected harmful factors
If approved antivirals (ribavirin, lopinavir-ritonavir) are used to treat ARDS, then viral infection is targeted, but side effects occur and treatment effectiveness is limited
Solution Approach 1:
Instead of using complex approved antivirals with known side effect profiles, the patent employs a simpler polysulfated polysaccharide structure that mimics the therapeutic effect of targeting viral infection and inflammation without reproducing the harmful side effects of conventional antivirals.
3Ease of operation
If lung ventilator strategies are used to support ARDS patients, then breathing is supported, but ventilation systems are insufficient during surges of critically ill patients
Solution Approach 1:
The pharmacological treatment enables patients to improve their own respiratory function through systemic anti-inflammatory and antifibrotic effects, reducing dependence on complex mechanical ventilation systems and allowing for more manageable supportive care during patient surges.
4Reliability
If existing pharmaceutical agents are used to treat ARDS, then some therapeutic effect is achieved, but safety and activity requirements are not fully met
Solution Approach 1:
Pentosan polysulfate represents a composite therapeutic approach combining anticoagulant, anti-inflammatory, and antifibrotic properties in a single polysulfated polysaccharide molecule, achieving multiple therapeutic effects simultaneously with an improved safety profile compared to conventional single-mechanism agents.
Data Source
AI summary
Methods for the treatment of Acute Respiratory Distress Syndrome (ARDS), particularly ARDS caused by viral infections such as influenza and SARS-CoV-2, comprising the administration of pentosan polysulfate (PPS) are provided. Some provided methods comprise the administration of sodium pentosan polysulfate. Prophylactic methods comprising the administration (for example, intra-nasally) of sodium pentosan polysulfate to inactivate a vims which is causative of ARDS are also provided.